Biopharmaceuticals

Sanofi's factory of the future named world's best overall facility by International Society for Pharmaceutical Engineering

Retrieved on: 
Tuesday, November 3, 2020
Life sciences, Health sciences, Articles, Biotechnology, Pharmacy, ISPE, Biopharmaceuticals, Biomanufacturing, Framingham, Massachusetts, Sanofi, Pharmaceutical industry

BRIDGEWATER, N.J., Nov. 3, 2020 /PRNewswire/ --Sanofi has won the prestigious International Society for Pharmaceutical Engineering (ISPE) Overall Facility of the Year Award for its digitally-enabled continuous biomanufacturing facility located in Framingham, Mass.

Key Points: 
  • BRIDGEWATER, N.J., Nov. 3, 2020 /PRNewswire/ --Sanofi has won the prestigious International Society for Pharmaceutical Engineering (ISPE) Overall Facility of the Year Award for its digitally-enabled continuous biomanufacturing facility located in Framingham, Mass.
  • The Facility Of the Year Award program showcases accomplishments in facility design, construction, and operation.
  • The Framingham facility , which opened in October 2019, is one of the world's first digital facilities using intensified, continuous biologics production technology.
  • The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.

BioLife Solutions to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020

Retrieved on: 
Thursday, October 29, 2020
Biopharmaceuticals, Bioproduction, Conference call

Management will provide an overview of the Company's financial results and a general business update.

Key Points: 
  • Management will provide an overview of the Company's financial results and a general business update.
  • To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings .
  • Alternatively, you may access the live conference call by dialing 1 (844) 825-0512 with the following Conference ID: 1296883.
  • BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services.

Vacaville Unveils California Biomanufacturing Center and New Nonprofit as It Begins Next Generation of Biotech Development in City

Retrieved on: 
Thursday, October 22, 2020
Articles, Life sciences, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Solano Community College, Vacaville, California, Manufacturing

With the California Biomanufacturing Center, we are building on our proven success with the industry to secure Vacavilles continued leadership as a biomanufacturing center going forward.

Key Points: 
  • With the California Biomanufacturing Center, we are building on our proven success with the industry to secure Vacavilles continued leadership as a biomanufacturing center going forward.
  • During the event, the California Biomanufacturing Center, Inc. and Solano Community College announced a memorandum of understanding to guide ongoing collaboration between the two.
  • Vacaville is the envy of many communities that have dreams of becoming a center for biomanufacturing, but lack the talent, commitment, and space to do so, said Gardner.
  • The center will not only work with industry to address manufacturing challenges but ensure that Vacaville remains a place for biomanufacturing to flourish.

BioLife Solutions SciSafe Division Secures $2.7 Million Cold Chain and Storage Contract for COVID-19 Vaccines

Retrieved on: 
Wednesday, October 14, 2020
Health sciences, Health, Biopharmaceuticals, Bioproduction, Medicinal chemistry, Articles, Therapy, CGMP

We are actively engaged in presenting SciSafe services to our marquee cell and gene therapy customers."

Key Points: 
  • We are actively engaged in presenting SciSafe services to our marquee cell and gene therapy customers."
  • Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant state-of-the-art sample management facilities.
  • With over 60 years combined experience specifically in life sciences, SciSafe personnel fully appreciate the vital requirements of all areas of specimen storage and cold chain management.
  • BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.

Biologics Outsourcing Market, 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 13, 2020
Health, General Health, Articles, Life sciences, Biotechnology, Pharmaceutical industry, Biopharmaceuticals, Pharmacy, Biomanufacturing

The "Biologics Outsourcing Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biologics Outsourcing Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics.
  • Biologics contract biomanufacturing services global market is expected to reach $57.1 billion by 2028 growing at a low teen CAGR from 2020 to 2028.
  • The cell line development service global market is expected to reach $1,702.2 million by 2028 growing at a double digit CAGR from 2020 to 2028.

Global Contract Biomanufacturing Services Market, 2020-2028: CMOs are Gaining Much Prominence to Meet the Increasing Demand for the Clinical and Commercial Supply of Biologics

Retrieved on: 
Thursday, October 8, 2020
Articles, Life sciences, Industries, Pharmaceutical industry, Biotechnology, Biopharmaceuticals, Boehringer Ingelheim, Biomanufacturing, Samsung Biologics, Fujifilm, Ingelheim am Rhein, Boehringer

DUBLIN, Oct. 8, 2020 /PRNewswire/ -- The "Contract Biomanufacturing Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 8, 2020 /PRNewswire/ -- The "Contract Biomanufacturing Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • There is a continued growth of the biopharmaceutical market which is expected to nearly double in the next 10 years.
  • Nowadays, CMOs are gaining much prominence to meet the increasing demand for the clinical and commercial supply of biologics.
  • Most of the CMO based biomanufacturing capacity is consolidated with major players like Samsung Biologics, Boehringer Ingelheim, Fujifilm and AbbVie.

Pharmaceutical Strategies Group Releases Proprietary Report on State of Specialty Spend and Trend

Retrieved on: 
Wednesday, October 7, 2020
Consulting, Health, Professional services, Pharmaceutical, Insurance, Life sciences, Articles, Biotechnology, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Pharmacy

Pharmaceutical Strategies Group (PSG) unveils new insights and opportunities for specialty drug savings with the release of the fourth annual State of Specialty Spend and Trend Report.

Key Points: 
  • Pharmaceutical Strategies Group (PSG) unveils new insights and opportunities for specialty drug savings with the release of the fourth annual State of Specialty Spend and Trend Report.
  • This highly anticipated report uses integrated pharmacy and medical claims data to share a complete picture of specialty spend and trend.
  • PSGs State of Specialty Spend and Trend Report details specialty drug utilization and gross spending through the lens of PSGs proprietary Artemetrx platform, which provides an integrated view of specialty costs.
  • This years State of Specialty Spend and Trend Report continues to reflect PSGs 25-year legacy of relentless client advocacy.

The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030, growing at a CAGR of 8.7%, claims Roots Analysis

Retrieved on: 
Tuesday, October 6, 2020
Articles, Business, Biotechnology, Pharmaceutical industry, Biopharmaceuticals, Economic globalization, Offshoring, Biomanufacturing, Outsourcing

LONDON, Oct. 6, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of the " Microbial Contract Biomanufacturing Market, 2020-2030 " report to its list of offerings.

Key Points: 
  • LONDON, Oct. 6, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of the " Microbial Contract Biomanufacturing Market, 2020-2030 " report to its list of offerings.
  • Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.
  • Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.
  • The USD 9.3 billion (by 2030) financial opportunity within the microbial contract biomanufacturing market has been analyzed across the following segments:

Contract Biomanufacturing Services Market, 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 1, 2020
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, Articles, Business, Economy, Biopharmaceuticals, Pharmaceutical industry, Biomanufacturing, Biotechnology, Food industry, Boehringer Ingelheim, Fujifilm, Boehringer, Outsourcing

The "Contract Biomanufacturing Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contract Biomanufacturing Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Asia-Pacific region is the fastest growing region in the contract biomanufacturing global market in 2020 and is expected to grow at high teen CAGR during the forecasted period.
  • Most of the CMO based biomanufacturing capacity is consolidated with major players like Samsung Biologics, Boehringer Ingelheim, Fujifilm and AbbVie.
  • There are certain restraints and threats as well which could potentially hamper the biomanufacturing outsourcing market.

BioLife Solutions Closes Acquisition of SciSafe, a High-Growth Biostorage Service Provider to the Cell and Gene Therapy Industry

Retrieved on: 
Thursday, October 1, 2020
Biopharmaceuticals, Bioproduction

SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021.

Key Points: 
  • SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021.
  • Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant state-of-the-art sample management facilities.
  • SciSafe has built flourishing relationships with over 300 of the world's leading and most admired organizations.
  • BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.